desoxycorticosterone pivalate

Small moleculeapproved

Approved

Aug 17, 1939

Desoxycorticosterone pivalate (DOCP) is a mineralocorticoid hormone and an analog of desoxycorticosterone. DOCP is a long-acting ester of desoxycorticosterone acetate (DOCA) which is recognized as having the same qualitative effects as the natural mineralocorticoid hormone aldosterone. It’s used as Percorten-V for replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency. Percorten-V is only available in the U.S., Canada, Australia and recently, Denmark. Percorten was originally developed for the treatment of Addison's disease in humans but the demand for it decreased significantly once Florinef was available. Unaware that their product was being prescribed “off-label” for the treatment of canine Addison’s Disease and faced with a decreased demand for Percorten, the manufacturer *almost* discontinued production until the veterinary community rose up and voiced their distress. Field trials were run and the FDA approved the use of Percorten-V (the "v" is for veterinary). DOCP like other adrenocorticoid hormones is thought to act by controlling the rate of synthesis of proteins. It reacts with receptor proteins in the cytoplasm to form a steroid-receptor complex. This complex moves into the nucleus, where it binds to chromatin that result in genetic transcription of cellular DNA to messenger RNA. The steroid hormones appear to induce transcription and synthesis of specific proteins, which produce the physiologic effects seen after administration. The most important effect of DOCP is to increase the rate of renal tubular absorption of sodium. This effect is seen most intensely in the thick portion of the ascending limb of the loop of Henle. It also increases sodium absorption in the proximal convoluted tubule but this effect is less important in sodium retention. Chloride follows the sodium out of the renal tubule. Another important effect of DOCP is enhanced renal excretion of potassium. This effect is driven by the resorption of sodium that pulls potassium from the extracellular fluid into the renal tubules, thus promoting potassium excretion. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1930s

  1. Aug 17, 1939

    Organon — Earliest FDA Approval

  2. Aug 17, 1939

    Organon — NDA Organization

1940s

  1. Dec 9, 1942

    Novartis — NDA Secondary Org

Indications

Approved for

Mechanism of action

Approval history

  • approvedAug 17, 1939

Chemistry & pharmacology

Loading structure…

SMILES

C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO
Mol. weight
330.4611 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 11-deoxycorticosterone pivalate
  • 11-deoxycorticosterone pivalate
  • cortexone
  • cortexone acetate
  • decosteron
  • decosterone
  • deoxycorticosterone
  • deoxycorticosterone acetate
  • deoxycorticosterone acetate
  • deoxycorticosterone acetate
  • deoxycorticosterone pivalate
  • deoxycorticosterone pivalate
  • deoxycorticosterone pivalate
  • deoxycorticosterone trimethylacetate
  • deoxycorticosterone trimethylacetate
  • deoxycorticosterone trimethylacetate
  • deoxycortolone pivalate
  • deoxycortolone pivalate
  • deoxycortone
  • deoxycortone
  • deoxycortone
  • deoxycortone acetate
  • deoxycortone pivalate
  • deoxycortone pivalate
  • deoxycortone pivalate
  • deoxycortone pivalate
  • deoxycortone trimethylacetate
  • deoxycortone trimethylacetate
  • deoxycortone trimethylacetate
  • desoxycorticosterone
  • desoxycorticosterone
  • desoxycorticosterone
  • desoxycorticosterone
  • desoxycorticosterone
  • desoxycorticosterone
  • desoxycorticosterone acetate
  • desoxycorticosterone acetate
  • desoxycorticosterone acetate
  • desoxycorticosterone acetate
  • desoxycorticosterone acetate
  • desoxycorticosterone acetate
  • desoxycorticosterone acetate
  • desoxycorticosterone acetate
  • desoxycorticosterone pivalate
  • desoxycorticosterone pivalate
  • desoxycorticosterone pivalate
  • desoxycorticosterone pivalate
  • desoxycorticosterone pivalate
  • desoxycorticosterone pivalate
  • desoxycorticosterone pivalate
  • desoxycorticosterone pivalate
  • desoxycorticosterone pivalate
  • desoxycorticosterone trimethylacetate
  • desoxycorticosterone trimethylacetate
  • desoxycorticosterone trimethylacetate
  • desoxycortisone pivalate
  • desoxycortone
  • desoxycortone
  • desoxycortone
  • desoxycortone
  • desoxycortone acetate
  • desoxycortone pivalate
  • desoxycortone pivalate
  • desoxycoticosterone trimethylacetate
  • doca
  • doca
  • doca
  • docp
  • docp
  • dtma
  • dtma
  • percorten
  • percorten
  • percoten pivalate
  • sincortex

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
NovartisFor profitNDA2Dec 9, 1942
OrganonFor profitNDAAug 17, 1939